CR20200287A - Receptores de células t restringidos a antígeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado - Google Patents
Receptores de células t restringidos a antígeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutadoInfo
- Publication number
- CR20200287A CR20200287A CR20200287A CR20200287A CR20200287A CR 20200287 A CR20200287 A CR 20200287A CR 20200287 A CR20200287 A CR 20200287A CR 20200287 A CR20200287 A CR 20200287A CR 20200287 A CR20200287 A CR 20200287A
- Authority
- CR
- Costa Rica
- Prior art keywords
- hla
- class
- human leukocyte
- leukocyte antigen
- ras
- Prior art date
Links
- 108091008874 T cell receptors Proteins 0.000 title abstract 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title abstract 4
- 239000000427 antigen Substances 0.000 title abstract 2
- 108091007433 antigens Proteins 0.000 title abstract 2
- 102000036639 antigens Human genes 0.000 title abstract 2
- 210000000265 leukocyte Anatomy 0.000 title abstract 2
- 206010039491 Sarcoma Diseases 0.000 title 1
- 241000124008 Mammalia Species 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 238000003259 recombinant expression Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4244—Enzymes
- A61K40/4253—GTPases, e.g. Ras or Rho
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10041—Use of virus, viral particle or viral elements as a vector
- C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762594244P | 2017-12-04 | 2017-12-04 | |
| PCT/US2018/063581 WO2019112941A1 (en) | 2017-12-04 | 2018-12-03 | Hla class i-restricted t cell receptors against mutated ras |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20200287A true CR20200287A (es) | 2020-11-11 |
Family
ID=64949411
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20200287A CR20200287A (es) | 2017-12-04 | 2018-12-03 | Receptores de células t restringidos a antígeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11466071B2 (enExample) |
| EP (1) | EP3720478A1 (enExample) |
| JP (3) | JP7385566B2 (enExample) |
| KR (1) | KR20200115484A (enExample) |
| CN (2) | CN111836638B (enExample) |
| AU (2) | AU2018378200B2 (enExample) |
| BR (1) | BR112020011111A2 (enExample) |
| CA (1) | CA3084246A1 (enExample) |
| CR (1) | CR20200287A (enExample) |
| EA (1) | EA202091335A1 (enExample) |
| IL (1) | IL275031A (enExample) |
| MA (2) | MA51043A (enExample) |
| MX (1) | MX2020005765A (enExample) |
| SG (1) | SG11202005236QA (enExample) |
| WO (1) | WO2019112941A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3635000A4 (en) * | 2017-05-16 | 2021-04-14 | The Johns Hopkins University | Manabodies and methods of using |
| US20220088190A1 (en) * | 2019-01-25 | 2022-03-24 | The Trustees Of The University Of Pennsylvania | Compositions and Methods for Targeting Mutant RAS |
| GB2596461B (en) | 2019-02-20 | 2023-09-27 | Fred Hutchinson Cancer Center | Binding proteins specific for RAS neoantigens and uses thereof |
| EP3760217A1 (en) * | 2019-07-01 | 2021-01-06 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Cd5 specific t cell receptor cell or gene therapy |
| CN112646024B (zh) * | 2019-10-10 | 2023-03-24 | 香雪生命科学技术（广东）有限公司 | 一种识别kras突变的t细胞受体及其编码序列 |
| CN112759641B (zh) * | 2019-11-01 | 2023-01-20 | 香雪生命科学技术（广东）有限公司 | 一种识别Kras G12V的高亲和力TCR |
| GB2609760A (en) * | 2020-02-12 | 2023-02-15 | Us Health | HLA Class I-restricted T cell receptors against RAS with G12D mutation |
| WO2021163477A1 (en) * | 2020-02-14 | 2021-08-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hla class i-restricted t cell receptors against ras with g12v mutation |
| CN115244075A (zh) * | 2020-02-26 | 2022-10-25 | 美国卫生和人力服务部 | 针对含有g12v突变的ras的hla ii类限制性t细胞受体 |
| EP4182029A1 (en) * | 2020-07-16 | 2023-05-24 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Hla class ii-restricted drb t cell receptors against ras with g12v mutation |
| AU2021351710A1 (en) * | 2020-10-02 | 2023-06-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hla class ii-restricted dq t cell receptors against ras with g13d mutation |
| KR102488353B1 (ko) * | 2020-10-08 | 2023-01-12 | 부산대학교 산학협력단 | 돌연변이 kras를 표적하는 펩타이드 및 이의 용도 |
| JP2023550515A (ja) * | 2020-11-24 | 2023-12-01 | シャンハイ、ケンパーソー、バイオテクノロジー、カンパニー、リミテッド | Ｒａｓ突然変異体エピトープペプチドおよびｒａｓ突然変異体を認識するｔ細胞受容体 |
| US20240175047A1 (en) | 2021-02-25 | 2024-05-30 | Alaunos Therapeutics, Inc. | Recombinant Vectors Comprising Polycistronic Expression Cassettes and Methods of Use Thereof |
| WO2022251283A1 (en) * | 2021-05-25 | 2022-12-01 | Memorial Sloan-Kettering Cancer Center | T cell receptors targeting ras mutations and uses thereof |
| US20250101078A1 (en) | 2022-01-21 | 2025-03-27 | T-Knife Gmbh | Antigen recognizing construct that binds specific peptide with determinable affinity and t cell receptor having antigenic specificity for kras as well as corresponding nucleic acid sequence, vector, host cell, pharmaceutical composition and kit |
| US20250145950A1 (en) | 2022-02-01 | 2025-05-08 | Alaunos Therapeutics, Inc. | Methods for Activation and Expansion of T Cells |
| CN117264043B (zh) * | 2022-06-14 | 2024-05-10 | 上海镔铁生物科技有限责任公司 | 靶向kras g12v突变多肽的t细胞受体及其用途 |
| CN115850444B (zh) * | 2022-09-15 | 2025-01-28 | 重庆医科大学 | Tcr或其抗原结合片段及其应用 |
| CN115960204B (zh) * | 2022-11-04 | 2023-08-25 | 新景智源生物科技(苏州)有限公司 | Kras_g12v突变抗原特异性tcr及其与cd8共表达重定向cd4 t细胞 |
| CN118852452A (zh) * | 2023-04-28 | 2024-10-29 | 北京鼎成肽源生物技术有限公司 | 靶向kras g12突变的tcr分子和细胞及其应用 |
| CN118909132A (zh) * | 2023-05-06 | 2024-11-08 | 北京鼎成肽源生物技术有限公司 | 靶向kras g12v突变的tcr分子和细胞及其应用 |
| WO2025056672A1 (en) * | 2023-09-15 | 2025-03-20 | Medigene Immunotherapies Gmbh | T-CELL RECEPTOR VARIANT AGAINST mKRAS7-16 G12V |
| WO2025056681A1 (en) * | 2023-09-15 | 2025-03-20 | Medigene Immunotherapies Gmbh | T-CELL RECEPTOR AGAINST mKRAS7-16 G12V AND G12C |
| WO2025125590A2 (en) * | 2023-12-15 | 2025-06-19 | Genovie Ab | Tcr recognizing g12v mutated ras and uses thereof |
| EP4570263A1 (en) * | 2023-12-15 | 2025-06-18 | Genovie AB | Tcrs recognizing g12v mutated ras and uses thereof |
| CN119350472B (zh) * | 2024-12-25 | 2025-04-04 | 北京可瑞生物科技有限公司 | 修饰的靶向kras g12v的t细胞受体或其片段以及用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1545204T3 (en) | 2002-09-06 | 2016-11-14 | The Government Of The Us Secretary Dept Of Health And Human Services | Immunotherapy with in vitro selected antigen-specific lymphocytes following non-myeloablative lymphodepletive chemotherapy |
| US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| CN103124740B (zh) * | 2010-09-21 | 2015-09-02 | 美国卫生和人力服务部 | 抗-ssx-2t细胞受体和相关材料及使用方法 |
| US20120244133A1 (en) | 2011-03-22 | 2012-09-27 | The United States of America, as represented by the Secretary, Department of Health and | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| PL3223850T3 (pl) * | 2014-11-26 | 2020-08-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Receptory limfocytów t przeciwko zmutowanemu kras |
| EP3901169A1 (en) * | 2015-09-15 | 2021-10-27 | The United States of America, as represented by the Secretary, Department of Health and Human Services | T cell receptors recognizing hla-cw8 restricted mutated kras |
| EP3394092A1 (en) * | 2015-12-23 | 2018-10-31 | Fred Hutchinson Cancer Research Center | High affinity t cell receptors and uses thereof |
| JP6697562B2 (ja) * | 2015-12-23 | 2020-05-20 | メディジーン イミュノテラピーズ ゲーエムベーハー | 樹状細胞組成物 |
| US12221627B2 (en) * | 2017-12-04 | 2025-02-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of enriching cell populations for cancer-specific T cells using in vitro stimulation of memory T cells |
-
2018
- 2018-12-03 CN CN201880087270.7A patent/CN111836638B/zh active Active
- 2018-12-03 CA CA3084246A patent/CA3084246A1/en active Pending
- 2018-12-03 EA EA202091335A patent/EA202091335A1/ru unknown
- 2018-12-03 WO PCT/US2018/063581 patent/WO2019112941A1/en not_active Ceased
- 2018-12-03 JP JP2020530325A patent/JP7385566B2/ja active Active
- 2018-12-03 KR KR1020207019185A patent/KR20200115484A/ko not_active Ceased
- 2018-12-03 CN CN202411410030.XA patent/CN119162251A/zh active Pending
- 2018-12-03 CR CR20200287A patent/CR20200287A/es unknown
- 2018-12-03 US US16/769,144 patent/US11466071B2/en active Active
- 2018-12-03 AU AU2018378200A patent/AU2018378200B2/en active Active
- 2018-12-03 MA MA051043A patent/MA51043A/fr unknown
- 2018-12-03 MA MA051042A patent/MA51042A/fr unknown
- 2018-12-03 SG SG11202005236QA patent/SG11202005236QA/en unknown
- 2018-12-03 EP EP18830062.8A patent/EP3720478A1/en active Pending
- 2018-12-03 BR BR112020011111-2A patent/BR112020011111A2/pt unknown
- 2018-12-03 MX MX2020005765A patent/MX2020005765A/es unknown
-
2020
- 2020-06-01 IL IL275031A patent/IL275031A/en unknown
-
2022
- 2022-09-12 US US17/931,391 patent/US20230026180A1/en active Pending
-
2023
- 2023-08-18 JP JP2023133670A patent/JP7620676B2/ja active Active
-
2025
- 2025-01-10 JP JP2025003895A patent/JP2025072378A/ja active Pending
- 2025-05-13 AU AU2025203455A patent/AU2025203455A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019112941A1 (en) | 2019-06-13 |
| CN119162251A (zh) | 2024-12-20 |
| CA3084246A1 (en) | 2019-06-13 |
| JP2021505136A (ja) | 2021-02-18 |
| JP7385566B2 (ja) | 2023-11-22 |
| SG11202005236QA (en) | 2020-07-29 |
| CN111836638A (zh) | 2020-10-27 |
| JP2023175703A (ja) | 2023-12-12 |
| KR20200115484A (ko) | 2020-10-07 |
| IL275031A (en) | 2020-07-30 |
| AU2018378200A1 (en) | 2020-07-02 |
| US20210079058A1 (en) | 2021-03-18 |
| BR112020011111A2 (pt) | 2020-11-17 |
| EP3720478A1 (en) | 2020-10-14 |
| US11466071B2 (en) | 2022-10-11 |
| US20230026180A1 (en) | 2023-01-26 |
| EA202091335A1 (ru) | 2020-10-15 |
| CN111836638B (zh) | 2024-10-29 |
| MA51042A (fr) | 2020-10-14 |
| MA51043A (fr) | 2020-10-14 |
| JP7620676B2 (ja) | 2025-01-23 |
| AU2018378200B2 (en) | 2025-02-27 |
| JP2025072378A (ja) | 2025-05-09 |
| MX2020005765A (es) | 2020-09-25 |
| AU2025203455A1 (en) | 2025-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20200287A (es) | Receptores de células t restringidos a antígeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado | |
| CR20240019A (es) | RECEPTORES DE CÉLULAS T RESTRINGIDAS A HLA DE CLASE II CONTRA RAS MUTADO (Divisional expediente 2020-0150) | |
| SA518391109B1 (ar) | Kras مستقبلات الخلايا التائية التي تميز hla-cw8 المطفرة المقيدة بـ | |
| CY1122720T1 (el) | Υποδοχεις τ κυτταρων που αναγνωριζουν περιορισμενη μαgε-α3 μηc ταξης ii | |
| MX2024005677A (es) | Receptores de celulas t que reconocen p53 mutado. | |
| CY1122790T1 (el) | Αντι-ανθρωπινου ιου των θηλωματων 16 ε7 τ κυτταρου υποδοχεις | |
| MX2017006865A (es) | Receptores de células t de kras anti-mutado. | |
| CA2848209C (en) | T cell receptors recognizing hla-a1- or hla-cw7-restricted mage | |
| CL2022002208A1 (es) | Receptor de células t restringido por hla de la clase i contra ras con mutación | |
| BR112021026408A2 (pt) | Receptores de célula t que reconhecem a mutação r175h ou y220c em p53 | |
| PE20190477A1 (es) | Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos | |
| MX2022010157A (es) | Receptores de células t restringidos a hla clase ii contra ras con mutación g12v. | |
| BR112022015897A2 (pt) | Receptores de célula t restritos à classe i de hla contra ras com mutação de g12v | |
| EA202192726A1 (ru) | Magea1-специфические т-клеточные рецепторы и их использование | |
| TR201905447T4 (tr) | Yeni mhc bağımsız tümörle ilişkili antijenler. | |
| FI3380115T3 (fi) | Peptidejä piwil1:stä | |
| WO2022015694A8 (en) | Hla class ii–restricted drb t cell receptors against ras with g12d mutation | |
| WO2016077525A3 (en) | Human anti-thyroglobulin t cell receptors | |
| UA124331C2 (uk) | Пептид, здатний зв'язуватися з молекулою головного комплексу гістосумісності (mhc) людини i класу | |
| WO2021262829A3 (en) | Hla class i-restricted t cell receptors against cd20 |